Areas of emerging interest in analgesia: cardiovascular complications.

作者: W. Stewart Hillis

DOI: 10.1097/00045391-200205000-00011

关键词:

摘要: Many people obtain symptomatic relief from acute, chronic, or recurring pain conditions by using an over-the-counter analgesic. As with the use of any drug, this involves achieving appropriate balance between potential benefit and risk harm. The adverse effects aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) in gastrointestinal (GI) tract are widely appreciated. On basis their pharmacology, however, these also have for causing cardiovascular system. This is particularly case certain overlapping populations (eg, elderly those cardiac failure, hypertension, renal impairment). And size exposed fact they comprise likely to require management because concomitant illnesses make implications analgesic potentially a more serious issue public health than recognized GI complications NSAID use. article discusses impact on system different classes analgesics (NSAIDs, new cyclooxygenase-2-selective inhibitors [CSIs], paracetamol) terms function, thrombotic cardioprotective potential, hypertension. It identifies patients at analgesic-related events, considers options managing mild-to-moderate pain. Unlike that NSAIDs CSIs, pharmacology paracetamol provides no signal should, therefore, be considered as first-line therapy disease.

参考文章(59)
G. Merrill, P. McConnell, K. Vandyke, S. Powell, Coronary and myocardial effects of acetaminophen: protection during ischemia-reperfusion. American Journal of Physiology-heart and Circulatory Physiology. ,vol. 280, ,(2001) , 10.1152/AJPHEART.2001.280.6.H2631
P.E. Lipsky, S.B. Abramson, R.N. Dubois, L.S. Simon, L.B.A. van de Putte, L.J. Crofford, The classification of cyclooxygenase inhibitors. The Journal of Rheumatology. ,vol. 25, pp. 2298- 2303 ,(1998)
C D Funk, D L Dewitt, T Hla, O Laneuville, D K Breuer, W L Smith, Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. Journal of Pharmacology and Experimental Therapeutics. ,vol. 271, pp. 927- 934 ,(1994)
Kenneth C. Lasseter, Francesca Catella-Lawson, Briggs W. Morrison, Barry J. Gertz, Shiv Kapoor, Garret A. Fitzgerald, Brendan McAdam, Dean Kujubu, Hui Quan, Lisa Antes, Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. Journal of Pharmacology and Experimental Therapeutics. ,vol. 289, pp. 735- 741 ,(1999)
Carlo Patrono, Michael J. Dunn, The clinical significance of inhibition of renal prostaglandin synthesis Kidney International. ,vol. 32, pp. 1- 12 ,(1987) , 10.1038/KI.1987.164
Juan Merlo, Kristian Broms, Ulf Lindblad, Agneta Björck-Linné, Hans Liedholm, Per Olof Östergren, Leif Erhardt, Lennart Råstam, Arne Melander, Association of outpatient utilisation of non-steroidal anti-inflammatory drugs and hospitalised heart failure in the entire Swedish population European Journal of Clinical Pharmacology. ,vol. 57, pp. 71- 75 ,(2001) , 10.1007/S002280100266
KENNETH L RADACK, Ibuprofen Interferes with the Efficacy of Antihypertensive Drugs Annals of Internal Medicine. ,vol. 107, pp. 628- 635 ,(1987) , 10.7326/0003-4819-107-5-628
A. Whelton, C. J. Maurath, K. M. Verburg, G. S. Geis, Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. American Journal of Therapeutics. ,vol. 7, pp. 159- 174 ,(2000) , 10.1097/00045391-200007030-00004
B. B. Weksler, A. J. Marcus, E. A. Jaffe, Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 74, pp. 3922- 3926 ,(1977) , 10.1073/PNAS.74.9.3922
Anthony G Johnson, Tuan V Nguyen, Richard O Day, Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis Annals of Internal Medicine. ,vol. 121, pp. 289- 300 ,(1994) , 10.7326/0003-4819-121-4-199408150-00011